Tumor-homing peptides guide nanoparticles to cancer cells for targeted drug delivery with fewer side effects | Research

The takeaway

Tumor-homing peptides target nanoparticle drug carriers to specific tumor markers on blood vessels, enabling selective chemotherapy delivery and tumor penetration while reducing off-target toxicity.

Targeted + penetrating
Tumor-homing peptides direct nanoparticles to tumors, while tumor-penetrating peptides drive them deep into tumor tissue to reach inaccessible cancer cells

What the researchers found

Tumor-homing peptides target receptors on tumor vasculature for selective NP delivery. Tumor-penetrating peptides promote extravasation and deep tissue penetration. Peptide targeting exploits molecular differences between healthy and malignant tissue. Review covers accumulation, barrier overcoming, and therapeutic outcomes.

Why it matters

Chemotherapy toxicity from non-specific distribution is a major clinical problem. Peptide-targeted delivery could transform cancer treatment by concentrating drugs at tumor sites while dramatically reducing side effects.

How the study worked

Narrative review of tumor-homing peptide applications in nanoparticle drug delivery for cancer therapy.

What this study cannot tell us

Review covers preclinical and early clinical work. In vivo efficacy varies. Manufacturing complexity and cost of peptide-NP conjugates remain challenges. Not all tumors express suitable peptide targets.

How to read the evidence

Narrative review of preclinical and early clinical data. Comprehensive overview but primarily preclinical evidence.

When this study was published

Published in 2025.

The bigger picture

Peptide-guided drug delivery represents a key frontier in precision oncology. By combining the specificity of peptide targeting with the drug-carrying capacity of nanoparticles, these systems could enable more effective cancer treatment with better quality of life.

Questions still open

Which tumor-homing peptides are closest to clinical approval?
Can peptide targeting be combined with immunotherapy approaches?
How do tumor-penetrating peptides compare to antibody-drug conjugates for deep tumor penetration?

Common questions

How do tumor-homing peptides work?

These peptides are like molecular addresses—they recognize and bind to specific markers on tumor blood vessels that are not present on normal blood vessels. When attached to drug-carrying nanoparticles, they direct the drugs specifically to the tumor site, reducing the damage to healthy tissues that causes chemotherapy side effects.

What are tumor-penetrating peptides?

These are a specialized type that not only targets tumors but also helps nanoparticles penetrate deep into tumor tissue. Regular drugs often only reach tumor cells near blood vessels, but tumor-penetrating peptides enable delivery to cells deep within the tumor that are otherwise unreachable.

Read the original research

Peptide-targeted nanoparticles for tumor therapy.

Journal of controlled release : official journal of the Controlled Release Society, 387, 114195

View on PubMed ↗Publisher’s paper ↗

Citation

Sidorenko, Valeria; Tobi, Allan; Sugahara, Kazuki N; Teesalu, Tambet. (2025). Peptide-targeted nanoparticles for tumor therapy.. Journal of controlled release : official journal of the Controlled Release Society, 387, 114195. https://doi.org/10.1016/j.jconrel.2025.114195